Symbols / RNAZ $9.35 -4.88%
RNAZ Chart
About
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 8.57M |
| Enterprise Value | 5.74M | Income | -27.13M | Sales | — |
| Book/sh | 1.71 | Cash/sh | 3.09 | Dividend Yield | — |
| Payout | 0.00% | Employees | 7 | IPO | — |
| P/E | — | Forward P/E | -15.58 | PEG | — |
| P/S | — | P/B | 5.47 | P/C | — |
| EV/EBITDA | -0.34 | EV/Sales | — | Quick Ratio | 1.02 |
| Current Ratio | 1.60 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -236.52 | EPS next Y | -0.60 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-04-15 16:00 | ROA | -232.54% |
| ROE | -17.63% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 916.97K |
| Shs Float | 832.42K | Short Float | 8.46% | Short Ratio | 0.14 |
| Short Interest | — | 52W High | 46.76 | 52W Low | 6.08 |
| Beta | 1.54 | Avg Volume | 268.60K | Volume | 5.80K |
| Target Price | — | Recom | None | Prev Close | $9.83 |
| Price | $9.35 | Change | -4.88% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$9.35
Latest analyst target
3. DCF / Fair value
$-180.92
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$9.35
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-04-16 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-13 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-02-07 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-02-06 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-12-18 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-10-24 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-09-06 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-05-29 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-04-16 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-04-03 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
- Colorectal cancer study to test RNA drug TTX-MC138 after standard treatment - Stock Titan hu, 05 Feb 2026 08
- The Technical Signals Behind (RNAZ) That Institutions Follow - Stock Traders Daily Sat, 14 Mar 2026 17
- TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of - PR Newswire ue, 03 Mar 2026 13
- TransCode Therapeutics stock soars after promising glioblastoma study - Investing.com ue, 06 Jan 2026 08
- TransCode Therapeutics Expands Pipeline With Oncolytic Virus Deal - The Globe and Mail Wed, 04 Mar 2026 08
- TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company - PR Newswire Wed, 08 Oct 2025 07
- TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset - Stocktwits Wed, 08 Oct 2025 07
- All You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to Buy - Yahoo Finance Fri, 18 Apr 2025 07
- Precision Trading with Transcode Therapeutics Inc. (RNAZ) Risk Zones - Stock Traders Daily ue, 03 Mar 2026 14
- TransCode Therapeutics appoints Jack E. Stover to board of directors - Investing.com Mon, 22 Dec 2025 08
- TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split - PR Newswire Mon, 05 May 2025 07
- Technical Reactions to RNAZ Trends in Macro Strategies - Stock Traders Daily Fri, 20 Feb 2026 08
- EXCLUSIVE: TransCode Therapeutics Reports Progress In Early-Stage Study For Lead Cancer Drug - Yahoo Finance hu, 01 May 2025 07
- Experimental RNA therapy extends survival in brain cancer animal tests - Stock Titan ue, 06 Jan 2026 08
- (RNAZ) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily Wed, 07 Jan 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -15.20M | -17.97M | -17.43M | -5.83M |
| TotalUnusualItems | -995.25K | 0.00 | 0.00 | -876.19K |
| TotalUnusualItemsExcludingGoodwill | -995.25K | 0.00 | 0.00 | -876.19K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -16.75M | -18.55M | -17.56M | -6.84M |
| ReconciledDepreciation | 534.86K | 516.75K | 98.61K | 42.47K |
| EBITDA | -16.19M | -17.97M | -17.43M | -6.71M |
| EBIT | -16.73M | -18.49M | -17.53M | -6.75M |
| NetInterestIncome | -623.09K | -50.61K | -11.58K | -94.41K |
| InterestExpense | 26.81K | 55.90K | 31.99K | 95.07K |
| InterestIncome | 684.00 | 5.29K | 20.41K | 664.00 |
| NormalizedIncome | -15.76M | -18.55M | -17.56M | -5.97M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -16.75M | -18.55M | -17.56M | -6.84M |
| TotalExpenses | 15.14M | 18.50M | 17.55M | 5.87M |
| TotalOperatingIncomeAsReported | -15.66M | -19.42M | -18.63M | -6.15M |
| DilutedAverageShares | 12.72K | 679.00 | 17.00 | 17.00 |
| BasicAverageShares | 12.72K | 679.00 | 17.00 | 17.00 |
| DilutedEPS | -1.32K | -27.31K | -1.03M | -402.55K |
| BasicEPS | -1.32K | -27.31K | -1.03M | -402.55K |
| DilutedNIAvailtoComStockholders | -16.79M | -18.55M | -17.56M | -6.84M |
| NetIncomeCommonStockholders | -16.79M | -18.55M | -17.56M | -6.84M |
| OtherunderPreferredStockDividend | 30.60K | 0.00 | ||
| NetIncome | -16.75M | -18.55M | -17.56M | -6.84M |
| NetIncomeIncludingNoncontrollingInterests | -16.75M | -18.55M | -17.56M | -6.84M |
| NetIncomeContinuousOperations | -16.75M | -18.55M | -17.56M | -6.84M |
| PretaxIncome | -16.75M | -18.55M | -17.56M | -6.84M |
| OtherIncomeExpense | -995.25K | -876.19K | ||
| SpecialIncomeCharges | 500.00 | 0.00 | 0.00 | -3.08K |
| GainOnSaleOfPPE | 500.00 | 0.00 | 0.00 | -3.08K |
| GainOnSaleOfSecurity | -995.75K | -873.11K | ||
| NetNonOperatingInterestIncomeExpense | -623.09K | -50.61K | -11.58K | -94.41K |
| TotalOtherFinanceCost | 596.96K | |||
| InterestExpenseNonOperating | 26.81K | 55.90K | 31.99K | 95.07K |
| InterestIncomeNonOperating | 684.00 | 5.29K | 20.41K | 664.00 |
| OperatingIncome | -15.14M | -18.50M | -17.55M | -5.87M |
| OperatingExpense | 15.14M | 18.50M | 17.55M | 5.87M |
| OtherOperatingExpenses | -524.06K | -923.03K | -1.08M | -278.33K |
| ResearchAndDevelopment | 9.71M | 12.26M | 10.23M | 2.75M |
| SellingGeneralAndAdministration | 5.95M | 7.15M | 8.40M | 3.40M |
| GeneralAndAdministrativeExpense | 5.95M | 7.15M | 8.40M | 3.40M |
| OtherGandA | 5.95M | 7.15M | 8.40M | 3.40M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 36.75K | 679.00 | 17.00 | 17.00 |
| ShareIssued | 36.75K | 679.00 | 17.00 | 17.00 |
| TotalDebt | 38.29K | 450.57K | 0.00 | |
| TangibleBookValue | -2.02M | 1.64M | 3.24M | 20.40M |
| InvestedCapital | -2.02M | 1.64M | 3.24M | 20.40M |
| WorkingCapital | 4.32M | 964.85K | 3.03M | 20.20M |
| NetTangibleAssets | -2.02M | 1.64M | 3.24M | 20.40M |
| CapitalLeaseObligations | 38.29K | 450.57K | 0.00 | |
| CommonStockEquity | -2.02M | 1.64M | 3.24M | 20.40M |
| TotalCapitalization | -2.02M | 1.64M | 3.24M | 20.40M |
| TotalEquityGrossMinorityInterest | -2.02M | 1.64M | 3.24M | 20.40M |
| StockholdersEquity | -2.02M | 1.64M | 3.24M | 20.40M |
| RetainedEarnings | -63.20M | -46.42M | -27.87M | -10.31M |
| AdditionalPaidInCapital | 61.18M | 48.06M | 31.11M | 30.71M |
| CapitalStock | 103.00 | 2.00 | 2.00 | 1.29K |
| CommonStock | 103.00 | 2.00 | 2.00 | 1.29K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 9.31M | 3.53M | 4.35M | 2.53M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 6.54M | 38.29K | 0.00 | 0.00 |
| DerivativeProductLiabilities | 6.54M | 0.00 | 0.00 | |
| NonCurrentAccruedExpenses | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 38.29K | 0.00 | |
| LongTermCapitalLeaseObligation | 0.00 | 38.29K | 0.00 | |
| CurrentLiabilities | 2.77M | 3.49M | 4.35M | 2.53M |
| CurrentDeferredLiabilities | 25.41K | 27.06K | 0.00 | 30.53K |
| CurrentDeferredRevenue | 25.41K | 27.06K | 0.00 | 30.53K |
| CurrentDebtAndCapitalLeaseObligation | 38.29K | 412.28K | ||
| CurrentCapitalLeaseObligation | 38.29K | 412.28K | 0.00 | |
| PayablesAndAccruedExpenses | 2.71M | 3.05M | 4.35M | 2.50M |
| CurrentAccruedExpenses | 2.71M | 3.05M | 4.35M | 2.50M |
| DuetoRelatedPartiesCurrent | 0.00 | |||
| TotalAssets | 7.29M | 5.17M | 7.59M | 22.94M |
| TotalNonCurrentAssets | 201.16K | 714.26K | 208.58K | 206.27K |
| NonCurrentPrepaidAssets | 111.86K | 111.86K | 0.00 | |
| NonCurrentDeferredAssets | 0.00 | |||
| NetPPE | 89.31K | 602.40K | 208.58K | 206.27K |
| AccumulatedDepreciation | -310.81K | -263.34K | -139.86K | -41.25K |
| GrossPPE | 400.12K | 865.74K | 348.44K | 247.52K |
| OtherProperties | 37.73K | 481.69K | 247.52K | |
| MachineryFurnitureEquipment | 362.39K | 384.05K | 348.44K | 247.52K |
| CurrentAssets | 7.09M | 4.46M | 7.38M | 22.73M |
| OtherCurrentAssets | 828.22K | 1.15M | 1.50M | 1.84M |
| PrepaidAssets | 454.06K | 539.10K | 554.33K | 70.87K |
| Receivables | 0.00 | 360.23K | 0.00 | |
| OtherReceivables | 360.23K | |||
| CashCashEquivalentsAndShortTermInvestments | 5.81M | 2.77M | 4.97M | 20.83M |
| CashAndCashEquivalents | 5.81M | 2.77M | 4.97M | 20.83M |
| CashFinancial | 5.81M | 2.77M | 4.97M | 20.83M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -13.36M | -18.11M | -15.86M | -5.52M |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 16.40M | 15.91M | 0.00 | 26.34M |
| CapitalExpenditure | -21.76K | -35.61K | -100.92K | -254.82K |
| InterestPaidSupplementalData | 16.63K | 32.86K | 37.12K | 17.87K |
| IncomeTaxPaidSupplementalData | 0.00 | |||
| EndCashPosition | 5.81M | 2.77M | 4.97M | 20.83M |
| BeginningCashPosition | 2.77M | 4.97M | 20.83M | 828.02K |
| ChangesInCash | 3.04M | -2.20M | -15.86M | 20.00M |
| FinancingCashFlow | 16.40M | 15.91M | 5.99K | 25.52M |
| CashFlowFromContinuingFinancingActivities | 16.40M | 15.91M | 5.99K | 25.52M |
| NetOtherFinancingCharges | -847.82K | |||
| ProceedsFromStockOptionExercised | 0.00 | 5.99K | 29.27K | |
| NetCommonStockIssuance | 16.40M | 15.91M | 0.00 | 26.34M |
| CommonStockIssuance | 16.40M | 15.91M | 0.00 | 26.34M |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -21.76K | -35.61K | -100.92K | -251.82K |
| CashFlowFromContinuingInvestingActivities | -21.76K | -35.61K | -100.92K | -251.82K |
| NetPPEPurchaseAndSale | -21.76K | -35.61K | -100.92K | -251.82K |
| SaleOfPPE | 0.00 | 3.00K | ||
| PurchaseOfPPE | -21.76K | -35.61K | -100.92K | -254.82K |
| OperatingCashFlow | -13.34M | -18.07M | -15.76M | -5.27M |
| CashFlowFromContinuingOperatingActivities | -13.34M | -18.07M | -15.76M | -5.27M |
| ChangeInWorkingCapital | -351.48K | -1.08M | 1.31M | 468.07K |
| ChangeInOtherWorkingCapital | -1.65K | 27.06K | -30.53K | 30.53K |
| ChangeInOtherCurrentLiabilities | -412.28K | -424.38K | 0.00 | |
| ChangeInOtherCurrentAssets | 0.00 | -111.86K | 0.00 | |
| ChangeInPayablesAndAccruedExpense | -343.12K | -1.30M | 1.84M | 2.34M |
| ChangeInAccruedExpense | 0.00 | 55.60K | ||
| ChangeInInterestPayable | 0.00 | 55.60K | ||
| ChangeInPayable | 1.84M | 2.29M | ||
| ChangeInAccountPayable | 1.84M | 2.29M | ||
| ChangeInPrepaidAssets | 405.57K | 362.91K | -144.44K | -1.90M |
| ChangeInReceivables | 0.00 | 360.23K | -360.23K | 0.00 |
| OtherNonCashItems | 3.79K | |||
| StockBasedCompensation | 1.70M | 1.04M | 395.33K | 186.00K |
| DepreciationAmortizationDepletion | 534.86K | 516.75K | 98.61K | 42.47K |
| DepreciationAndAmortization | 534.86K | 516.75K | 98.61K | 42.47K |
| Depreciation | 534.86K | 516.75K | 98.61K | 42.47K |
| OperatingGainsLosses | 1.54M | 876.19K | ||
| GainLossOnInvestmentSecurities | 1.54M | 873.11K | ||
| GainLossOnSaleOfPPE | 0.00 | 3.08K | ||
| NetIncomeFromContinuingOperations | -16.75M | -18.55M | -17.56M | -6.84M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for RNAZ
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|